Vimarsana
Biggest News Aggregation in the World

Nat Rev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nat Rev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nat Rev Today - Breaking & Trending Today

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Is Tylenol Safe During Pregnancy? Dexamphetamine? Studies Say Yes. - Vimarsana News

Is Tylenol Safe During Pregnancy? Dexamphetamine? Studies Say Yes.

Is Tylenol safe during pregnancy? Two new studies found dexamphetamine and acetaminophen exposure during pregnancy does not increase ADHD, autism risks.

Chronic Kidney Disease: Perspectives for World Kidney Day 2024 - Vimarsana News

Chronic Kidney Disease: Perspectives for World Kidney Day 2024

World Kidney Day is a good opportunity to reflect on Chronic Kidney Disease and the fact that it is increasing worldwide as a cause of death, writes Dr Sinead Stoneman

Source: imt.ie
AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder - Vimarsana News

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here.